Greenebaum Cancer Center at University of Maryland Medical Center — Baltimore, Maryland

Greenebaum Cancer Center at University of Maryland Medical Center is a clinical research site located in Baltimore, Maryland, United States 21201.

Crixeo Health Trust Score: 90/100 (GOOD). This profile has not yet been claimed by the site owner.

Greenebaum Cancer Center at University of Maryland Medical Center has participated in 124 clinical trials with 4 currently active.

Therapeutic areas: Breast Cancer, Endometrial Cancer, Lung Cancer.

Sponsors: SWOG Cancer Research Network, Radiation Therapy Oncology Group, Alliance for Clinical Trials in Oncology.

Sponsor Feasibility Report

Trust Score: 90/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Greenebaum Cancer Center at University of Maryland Medical Center?

Greenebaum Cancer Center at University of Maryland Medical Center has a Crixeo Trust Score of 90/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Greenebaum Cancer Center at University of Maryland Medical Center conducted?

Greenebaum Cancer Center at University of Maryland Medical Center has 124 clinical trials on record, with 4 currently active. Their work covers Breast Cancer, Endometrial Cancer, Lung Cancer.

Is Greenebaum Cancer Center at University of Maryland Medical Center accredited by Crixeo Health?

Yes — Greenebaum Cancer Center at University of Maryland Medical Center holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Greenebaum Cancer Center at University of Maryland Medical Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.